In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments
Here, we report the in-host hepatitis E virus (HEV) quasispecies evolution in a chronically infected patient who was treated with three different regimens of ribavirin (RBV) for nearly 6 years. Sequential plasma samples were collected at different time points and subjected to RNA extraction and deep sequencing using the MiSeq Illumina platforms. Specifically, we RT-PCR amplified a single amplicon from the core region located in the open-reading frame 2 (ORF2). At the nucleotide level (genotype), our analysis showed an increase in the number of rare haplotypes and a drastic reduction in the frequency of the master (most represented) sequence during the period when the virus was found to be insensitive to RBV treatment. Contrarily, at the amino acid level (phenotype), our study revealed conservation of the amino acids, which is represented by a high prevalence of the master sequence. Our findings suggest that using mutagenic antivirals concomitant with high viral loads can lead to the selection and proliferation of a rich set of synonymous haplotypes that express the same phenotype. This can also lead to the selection and proliferation of conservative substitutions that express fitness-enhanced phenotypes. These results have important clinical implications, as they suggest that using mutagenic agents as a monotherapy treatment regimen in the absence of sufficiently effective viral inhibitors can result in diversification and proliferation of a highly diverse quasispecies resistant to further treatment. Therefore, such approaches should be avoided whenever possible.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 24(2023), 24 vom: 06. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Colomer-Castell, Sergi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
49717AWG6K |
|---|
| Anmerkungen: |
Date Completed 25.12.2023 Date Revised 25.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms242417185 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366296728 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366296728 | ||
| 003 | DE-627 | ||
| 005 | 20231227141132.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms242417185 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1238.xml |
| 035 | |a (DE-627)NLM366296728 | ||
| 035 | |a (NLM)38139013 | ||
| 035 | |a (PII)17185 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Colomer-Castell, Sergi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In-Host HEV Quasispecies Evolution Shows the Limits of Mutagenic Antiviral Treatments |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2023 | ||
| 500 | |a Date Revised 25.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Here, we report the in-host hepatitis E virus (HEV) quasispecies evolution in a chronically infected patient who was treated with three different regimens of ribavirin (RBV) for nearly 6 years. Sequential plasma samples were collected at different time points and subjected to RNA extraction and deep sequencing using the MiSeq Illumina platforms. Specifically, we RT-PCR amplified a single amplicon from the core region located in the open-reading frame 2 (ORF2). At the nucleotide level (genotype), our analysis showed an increase in the number of rare haplotypes and a drastic reduction in the frequency of the master (most represented) sequence during the period when the virus was found to be insensitive to RBV treatment. Contrarily, at the amino acid level (phenotype), our study revealed conservation of the amino acids, which is represented by a high prevalence of the master sequence. Our findings suggest that using mutagenic antivirals concomitant with high viral loads can lead to the selection and proliferation of a rich set of synonymous haplotypes that express the same phenotype. This can also lead to the selection and proliferation of conservative substitutions that express fitness-enhanced phenotypes. These results have important clinical implications, as they suggest that using mutagenic agents as a monotherapy treatment regimen in the absence of sufficiently effective viral inhibitors can result in diversification and proliferation of a highly diverse quasispecies resistant to further treatment. Therefore, such approaches should be avoided whenever possible | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a deep sequencing | |
| 650 | 4 | |a fitness | |
| 650 | 4 | |a mutagens | |
| 650 | 4 | |a quasispecies | |
| 650 | 4 | |a rare haplotypes | |
| 650 | 4 | |a variability | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Mutagens |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 700 | 1 | |a Gregori, Josep |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Cehic, Damir |e verfasserin |4 aut | |
| 700 | 1 | |a Riveiro-Barciela, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Rando-Segura, Ariadna |e verfasserin |4 aut | |
| 700 | 1 | |a Vico-Romero, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Campos, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Ibañez-Lligoña, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Adombi, Caroline Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Cortese, Maria Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Tabernero, David |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Juan Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Frias, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Quer, Josep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 24(2023), 24 vom: 06. Dez. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:24 |g day:06 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms242417185 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 24 |b 06 |c 12 | ||